Atrium Health Levine Cancer Center
Welcome,         Profile    Billing    Logout  
 1 Trial 
1 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Granger, Chari
NCT06001788: Safety and Tolerability of Ziftomenib Combinations in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Recruiting
1
171
Europe, US
Ziftomenib, KO-539, Fludarabine, Idarubicin, Cytarabine, Gilteritinib, Xospata, Granulocyte colony-stimulating factor
Kura Oncology, Inc.
AML, AML with Mutated NPM1, Hematologic Malignancy, KMT2Ar, NPM1 Mutation, MLL Rearrangement, Leukemia, Acute Myeloid Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Acute Leukemia, Neoplasms by Histologic Type
08/26
08/27
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Granger, Chari
NCT06001788: Safety and Tolerability of Ziftomenib Combinations in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Recruiting
1
171
Europe, US
Ziftomenib, KO-539, Fludarabine, Idarubicin, Cytarabine, Gilteritinib, Xospata, Granulocyte colony-stimulating factor
Kura Oncology, Inc.
AML, AML with Mutated NPM1, Hematologic Malignancy, KMT2Ar, NPM1 Mutation, MLL Rearrangement, Leukemia, Acute Myeloid Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Acute Leukemia, Neoplasms by Histologic Type
08/26
08/27

Download Options